Prevalence of Vancomycin-Resistant Enterococci in Europe
|
|
- Sheena West
- 6 years ago
- Views:
Transcription
1 Eur J Clin Microbiol Infect Dis (2000) 19 : Q Springer-Verlag 2000 Article Prevalence of Vancomycin-Resistant Enterococci in Europe M.A. Schouten, J.A.A. Hoogkamp-Korstanje, J.F.G. Meis, A. Voss, and the European VRE Study Group Abstract The aim of the present study was to determine the prevalence of vancomycin-resistant enterococci (VRE) in Europe. Overall, 49 laboratories in 27 countries collected 4,208 clinical isolates of enterococci. Species identification, susceptibility testing, and van gene determination by polymerase chain reaction were performed in a central laboratory. Overall, 18 vana and 5 vanb isolates of VRE were found. The prevalence of vana VRE was highest in the UK (2.7%), while the prevalence of vanb VRE was highest in Slovenia (2%). Most vana and vanb VRE were identified as Enterococcus faecium. Most VRE isolates originated from the patient s urogenital tract, skin, or digestive tract. VRE were equally distributed among clinical departments, with no clear preponderance in any single patient group. A total of 71 isolates containing the vanc gene were identified. The prevalence of vanc VRE was highest in Latvia and Turkey, where rates were 14.3 and 11.7%, respectively. Two-thirds of these isolates were identified as Enterococcus gallinarum and one-third as Enterococcus casseliflavus; the majority of these isolates were cultured from feces. Almost all isolates were obtained from hospitalized patients, mostly children. The highest prevalence of high-level gentamicin-resistant enterococci was seen in Turkey and Greece. In general, the distribution of this resistance type seemed unrelated to the occurrence of VRE. The prevalence of vana/ vanb VRE in Europe is still low; the majority of the VRE isolates exhibit the vanc genotype and colonize the gastrointestinal tract of hospitalized children. Introduction During the last decade, enterococci have become important nosocomial pathogens, representing the third leading cause of bacteremia and the second leading cause of urinary tract infections in the USA [1, 2]. This increasing prevalence has been paralleled by the occurrence of vancomycin-resistant strains (VRE), which were first reported in 1988 [3, 4]. Since then, strains resistant to teicoplanin and/or vancomycin have appeared throughout the world. VRE frequently M.A. Schouten, J.A.A. Hoogkamp-Korstanje, J.F.G. Meis, A. Voss (Y) University Medical Center St Radboud, Department of Medical Microbiology, PO Box 9101, 6500 HB Nijmegen, The Netherlands a.voss6mmb.azn.nl Tel: c Fax: c express additional resistance to multiple antibiotics, including ampicillin and aminoglycosides (including high-level resistance) [5 20], thereby causing therapeutical problems. Between 1989 and 1993, the incidence of VRE colonization among patients in U.S. hospitals increased 26-fold, from 0.3 to 7.9% [21]. Higher incidences (13.6%) were reported among patients admitted to intensive care units (ICUs) [21]. Whereas the rapid emergence of VRE in the USA is probably attributable to the excessive use of vancomycin and/or cephalosporins [22, 23], the occurrence of VRE in Europe is possibly boosted by the (former) use of glycopeptide analogs (e.g. avoparcin) as growth promoters in bioindustry and the consequent transmission of VRE via the food chain [24 26]. Until now, information on the prevalence of VRE in Europe has been limited to the results of several studies performed in single European countries or as a part of unspecific antimicrobial susceptibility surveys. In general, the
2 817 prevalence seems to be low, ranging from 2 to 5% in the community as well as in hospitalized patients [8, 9, 12 14, 16]. Still, higher prevalences ( 1 30%) in hospitals, while unusual, have been reported [27]. The aim of the present study was to determine the prevalence of both VRE and high-level aminoglycoside-resistant enterococci in a prospective, pan-european study, using a single center for identification, susceptibility testing, and further evaluation of all clinical isolates suspected to be enterococci. Materials and Methods Enterococcal Strain Collection. From 1 January to 1 April 1997, a total of 61 European hospitals were invited to participate in collecting enterococci. Strains had to be isolated from clinical material, with a maximum of 100 consecutive isolates per center and one isolate per patient. A patient record form was used to collect additional information on patient demography, clinical details, and previous glycopeptide usage. Species Identification. Collected strains, presumptively identified as Enterococcus species, were sent to our laboratory, where confirmation of the genus and identification to species level was performed by biochemical characterization using Facklam s recommendations [28] and additional testing for methyl-a-dglucopyranoside [29]. In addition, identification of all VRE isolates was confirmed by the API 20 Strep system (biomérieux, France). The final identification of Enterococcus casseliflavus and Enterococcus gallinarum was based on PCR results (vanc1p Enterococcus gallinarum, vanc2penterococcus casseliflavus) when biochemical reaction patterns were nondiscriminatory. Susceptibility Testing. Susceptibility testing of vancomycin (Sigma Chemie, The Netherlands), teicoplanin (Hoechst Marion Merrell Dow, The Netherlands), amoxicillin (SmithKline Beecham, UK), and gentamicin (Ducheva, The Netherlands) was performed by microbroth dilution [30] with Mueller-Hinton broth (BBL ; Becton & Dickinson, The Netherlands), following NCCLS guidelines. Drugs were reconstituted according to the manufacturers directions. High-level gentamicin resistance was defined as MIC 6500 mg/l. Plates were incubated at 37 7C, and growth was assessed after 24 h of incubation. All strains for which the MIC of vancomycin was 14 mg/l were also tested by the E test (AB Biodisk, Sweden), using an inoculum of 0.5 McFarland turbidity and Mueller-Hinton agar (BBL ; Becton & Dickinson). After 24 h of incubation, the MIC was obtained by rounding to the nearest higher doubling dilution. Enterococcus faecalis ATCC and Staphylococcus aureus ATCC were used as reference strains. The presence of van genes was investigated by PCR as described elsewhere [31], using primers from the vana, vanb, and vanc genes. Table 1 Distribution of the 4,208 enterococcal isolates included in the study Enterococcus species No. of isolates Percent E. faecalis 3, E. faecium E. gallinarum E. durans E. casseliflavus E. avium E. faecalis variant E. hirae E. pseudavium E. mundtii E. raffinosum (np49), while the highest number originated from Germany (np371, from 4 centers). Most participating laboratories (87%) were located at teaching hospitals. Eighty-three percent (np3,493) of all isolates were identified as Enterococcus faecalis. The second most frequently isolated species was Enterococcus faecium, accounting for 13.6% (np574) of all enterococcal isolates (Table 1). Vancomycin-Resistant Enterococci. The MIC of vancomycin was 68 mg/l for 51 strains: 18 possessed a vana gene, 5 a vanb gene, and the remaining 28 a vanc gene. Most vana and all vanb VRE were identified as Enterococcus faecium (Table 2). In one isolate, which was initially identified as Enterococcus casseliflavus (vancomycin MIC, 16 mg/l; teicoplanin MIC, 1 mg/l), a multiplex PCR detected the vana gene but not the vanc gene. This strain was classified as vana VRE. The majority of the vanc VRE were Enterococcus gallinarum strains. In addition to the 28 vanc VRE, we identified 43 isolates, either Enterococcus gallinarum or Enterococcus casseliflavus, that were vanc positive but for which the MICs of vancomycin were ^4 mg/l. In the analysis of results, vana- and vanb-containing enterococci are grouped together and will be evaluated separately from the 71 vanc-containing Enterococcus gallinarum and Enterococcus casseliflavus isolates, which are grouped together irrespective of the vancomycin MICs for these isolates. The prevalence of vana and vanb VRE in Europe is shown in Figure 1. Overall, vana/vanb-vre were isolated in only 10 of the 27 participating countries. vana VRE were isolated in eight countries (Table 3). Results Forty-nine centers from 27 European countries participated (range, 1 4 centers per country), collecting a total of 4,208 enterococcal strains. An average of isolates (SD 89.3) per country were included. The lowest number of isolates from a single country originated from Latvia (np42), followed by Greece Table 2 Species distribution of vancomycin-resistant enterococci Resistance type No. (%) of isolates E. faecalis E. faecium E. casseliflavus E. gallinarum vana 2 (11) 15 (83) 1 (6) vanb 5 (100) vanc 22 (31) 49 (69)
3 818 Figure 1 Prevalence (%) of VRE (vanacvanb) in Europe (including Turkey and Israel) The UK had the highest prevalence (2.9%), followed by Israel (2%). The other European countries had prevalence rates of 1% or lower. vanb VRE were isolated in four countries (Slovenia, Finland, Sweden, UK), of which Slovenia had the highest prevalence (2%). vanc VRE were encountered in most countries participating, with the exception of Belgium, Finland, Greece, Slovenia, Sweden, and Switzerland (Table 3). The highest prevalence was seen in Latvia (14.3%), followed by Turkey (11.7%). The highest prevalence of high-level gentamicinresistant enterococci (HLGRE) was found in Greece (48.9%), followed by Turkey (48.1%). The lowest prevalence of HLGRE was found in Norway, followed by Russia, Denmark, and France (Table 3). Table 4 shows the distribution of glycopeptide-susceptible enterococci and VRE by patient characteristics and culture sites. In general, the isolates were equally distributed between the sexes, with slightly more men being colonized with vanc VRE. Susceptible and resistant isolates originated mainly from patients between 16 and 65 years of age, with the exception of vanc VRE, which were isolated predominately from patients between the ages of 1 and 16. Compared to the age distribution of GSE, the prevalence of VRE was slightly lower among elderly patients. Three-quarters of the glycopeptide-susceptible enterococci were isolated from hospitalized patients, whereas 83% of all vana/vanb VRE were isolated from admitted patients, including all vanb isolates. The percentage of vanc VRE originating from hospitalized patients was even higher, namely 91%. Overall, glycopeptide use was documented in 3.5% of the patients whose isolates were included in the study. In 10% of the patients with vanc VRE and in 16% of the patients with vana VRE, prior glycopeptide use was documented. vana/vanb VRE were equally distributed throughout nine different departments. vanc VRE were distributed among 12 departments, with one-third of these
4 819 Table 3 Distribution of vancomycin-resistant enterococci (VRE) and high-level gentamicin-resistant enterococci (HLGRE) by country Country No. (%) of isolates VanA VanB VanC HLGRE Austria 1 (0.7) 26 (17.6) Belgium 1 (1) 8 (8.0) Bulgaria 5 (5.3) 32 (33.7) Croatia 1 (1.1) 25 (26.9) Czech Republic 1 (1) 3 (3.0) 29 (29.3) Denmark 1 (0.4) 12 (5.3) Finland 1 (1) 37 (18.7) France 1 (0.3) 16 (5.5) 17 (5.9) Germany 3 (0.5) 9 (3.3) 68 (18.3) Greece 24 (48.9) Hungary 2 (1.0) 55 (27.9) Israel 4 (2) 1 (0.5) 43 (21.9) Italy 3 (1) 2 (0.7) 54 (18.9) Latvia 6 (14.3) 12 (28.6) Lithuania 3 (4.0) 29 (38.7) Netherlands 1 (0.4) 75 (27.0) Norway 1 (1.0) 1 (1.0) Poland 1 (0.5) 50 (26.7) Portugal 1 (1.0) 24 (24.7) Russia 1 (1.5) 1 (1.5) Slovak Republic 1 (1) 3 (3.0) 8 (8.4) Slovenia 2 (2) 25 (26.3) Spain 2 (0.9) 62 (27.7) Sweden 1 (0.3) 19 (19.0) Switzerland 23 (7.9) Turkey 9 (11.7) 37 (48.1) UK 4 (2.7) 1 (0.7) 2 (1.5) 50 (36.8) isolates originating from pediatric patients. No VRE were found among patients from neurologic/neurosurgical ICUs, gynecology, or geriatric wards. The urogenital tract was the major source of the enterococci isolated, independent of their resistance to glycopeptides. Significantly more vana/vanb VRE were isolated from patients blood and skin cultures. vanc VRE could be isolated from five different sites, with the majority (58%) from the digestive tract, followed by the urogenital tract (20%). Microepidemiological Evaluation. A more detailed evaluation of the British vana VRE, which originated from two different centers, showed that the four isolates came from four different departments, different body sites, and from patients of different age groups, thus giving no indication of a cluster or epidemiological relatedness. Similarly, no epidemiological relation was seen among the Israeli VRE isolates. Multiple patients with vanb VRE were found only in Slovenia. Two Enterococcus faecium isolates came from the same center and culture source (skin), but from different departments. Results of the PCR fingerprinting suggested that they were not related. When looking further at vanc VRE, it appeared that the 33% peak prevalence seen among children included isolates recovered from the digestive tract (74%), the urogenital tract (17%), and blood (9%). Strains isolated from the last two sites were all vancomycin susceptible, while half of the strains from the digestive tract were vancomycin resistant (MIC, 8 mg/l). The resistant strains (np8), isolated from the digestive tract, originated from a single French center and were distributed equally between boys and girls. All strains were identified as Enterococcus gallinarum. The susceptible strains (np7) came from the same French center and were identified either as Enterococcus casseliflavus or Enterococcus gallinarum. The vanc VRE isolated from the urogenital tract comprised four strains, three of which were derived from one Turkish center. All three isolates were identified as Enterococcus gallinarum. The blood isolates (np2) came from the same Turkish center and were also identified as Enterococcus gallinarum. The high prevalence of vanc VRE in Latvia (14.3%) resulted from six strains isolated from the digestive tract of children. One child was admitted to the pediatric ICU; wards to which the other children were admitted were not specified. Both Enterococcus gallinarum and Enterococcus casseliflavus were isolated. Discussion Since the first reports in 1988 [3, 4], VRE has become a common clinical pathogen in the USA [1, 2, 21]. Whereas VRE in the USA seems to be a hospital problem, probably caused by the extensive use of vancomycin and other antimicrobial agents such as cephalosporins [22, 23], VRE in Europe are present among hospitalized as well as nonhospitalized patients [16]. Furthermore, the prevalence of VRE in Europe is comparably low, but this assumption is based solely on studies performed in single European countries or conducted as a part of unspecific antimicrobial susceptibility surveys [8, 9, 12 14, 16]. Until now, no prospective pan-european VRE surveillance study using a central laboratory for identification and susceptibility testing has been performed. Furthermore, not all investigators differentiate between the particular types of VRE. Certainly, vana- and vanbcontaining enterococci, especially the primarily multiresistant Enterococcus faecium strains, have a much higher clinical impact than vanc VRE, such as Enterococcus casseliflavus or Enterococcus gallinarum. The latter only rarely cause clinical infections. In the present study, only 23 (0.5%) isolates were of the vana/vanb resistance type, whereas the overall prevalence of van-gene-containing VRE (23 vana/vanb c 71 vanc isolates) would have been 2.2%. Thus, the inclusion of all enterococci that harbor a van gene may lead to an overestimation of the clinical problem.
5 820 Table 4 Distribution of enterococci by patient characteristics and clinical variables (%) Variable vanacvanb VRE vanc VRE VSE Total (np23) (np71) (np4,114) (np4,208) Sex Male Female Age ~1 year years years years Glycopeptide use Yes No Unknown Hospitalized Yes No Source of isolate Blood Digestive tract Respiratory tract Skin Spinal fluid Urogenital tract Other Unknown Department Internal medicine Hematology Geriatrics Intensive care Surgery Orthopedics Urology Gynecology Pediatrics Other VRE, vancomycin-resistant enterococci; VSE, vancomycin-sensitive enterococci Furthermore, only 28 of the 71 (40%) vanc-containing isolates were actually vancomycin resistant (MIC68 mg/l) and therefore rightfully referred to as VRE. In contrast to the occurrence of MRSA among European countries [32], the prevalence of VRE shows no special geographical distribution. Theoretically, VRE and MRSA could be two links of the same chain, since a high MRSA prevalence may augment an excessive vancomycin use that consequently could lead to the occurrence of VRE. Such a phenomenon is clearly not reflected in the distribution of VRE among European countries, as shown in the present study. In general, vana/vanb VRE seem to be equally distributed with regard to patients sex and age, clinical department of origin, and site of isolation. An exception is the morethan-twofold higher occurrence of vana/vanb VRE in blood cultures, possibly indicating a higher risk of serious infections due to enterococcal isolates resistant to even the ultimate treatment option. The distribution of HLGRE in Europe follows neither that of VRE nor that of MRSA. Some countries like the UK have a high prevalence of VRE and HLGRE, while others, like Greece, have no VRE yet have the highest prevalence of HLGRE in Europe. Thus, no correlation between the prevalence of any type of VRE and HLGRE can be made. The use of vancomycin or cephalosporins has been described as a risk factor for the selection of VRE [33]. In the present study, patients colonized or infected with VRE (especially vana/vanb VRE) had a higher rate of prior glycopeptide use, namely 13% versus 3.5% in patients with vancomycin-susceptible isolates. With regard to the above-mentioned study, these findings might be accurate, but the number of patients for whom no data on vancomycin use could be documented is too high to consider these results reliable. In contrast to vana/vanb VRE, which were equally distributed by patient and clinical characteristics, vanc VRE were found more frequently in young males. Accordingly, isolates came predominately from pediatric patients, with more than 50% of the patients ranging from 1 to 16 years of age. The proportion of vanc VRE in children, therefore, was 3.2- and 3.9-fold
6 821 higher than the proportion vana and vanb VRE, respectively. Furthermore, with only 13.2% of all enterococci isolated from the digestive tract, the proportion of vanc VRE isolated from this source was 4.4-fold higher. In general, the pan-european VRE prevalence is still very low, but considering the high prevalence of HLGRE in Europe, enterococci may pose a serious threat to the treatment of patients with invasive infections. In such patients, combination therapy may be warranted, especially in those countries where the prevalence of both resistance types is high. Acknowledgement The members of the European VRE Study Group are as follows: Austria: Dr. C. Jebelean, Prof. Dr. M. Rotter; Belgium: Prof. Dr. M.J. Struelens; Bulgaria: Dr. E.E. Keuleyan; Croatia: Dr. A. Boras; Czech Republic: Prof. Dr. J. Schindler; Denmark: Dr. A. Bremmelgaard, Dr. N. Frimodt- Moller, Dr. A. Lester; Finland: Dr. O.O. Liimatainen, Dr. J. Vuopio-Varkila; France: Prof. Dr. A. Andremont/Dr. C. Muller- Serleys, Prof. Dr. J. Etienne, Dr. J. Raymond; Germany: Dr. L. Bader, Prof. Dr. R. Lütticken/Dr. R.R. Reinert, Prof. Dr. G. Peters/Dr. R. Gross, Prof. Dr. Shah; Greece: Dr. G. Syrogiannopoulos, Dr. O. Vavatsi-Manou; Hungary: Dr. A. Marton, Prof. Dr. E. Nagy; Israel: Dr. C. Block, Prof. Dr. P. Yagupsky; Italy: Prof. Dr. G.A. Botta, Prof. Dr. G. Marchiaro, Prof. Dr. S. Stefani; Latvia: Dr. D. Gardovska/Dr. L. Drukalska; Lithuania: Prof. Dr. V. Usonis; Netherlands: Dr. H.P. Endtz, Dr. J.G.M. Koeleman; Norway: Dr. A. Sundsfjord; Poland: Dr. M. Basta, Dr. E. Torbicka, Dr. A. Rokosz, Dr. A. Sawicka-Grzelak; Portugal: Prof. J. Melo-Cristino; Russia: Dr. I.A. Popova; Slovak Republic: Prof. Dr. V. Krcmercy; Slovenia: Prof. Dr. M. Gubina; Spain: Dr. F. Asensi-Botet, Prof. Dr. C. Riestra, Dr. J. Villa; Sweden: Prof. Dr. L.G. Burman, Dr. M.H. Laurel, Dr. M. Rylander; Switzerland: Dr. R. Frei; Turkey: Dr. G. Kanra; UK: Dr. P.R. Chadwick, Dr. E.H. Price References 1. Chenoweth C, Schaberg DR: The epidemiology of enterococci. European Journal of Clinical Microbiology & Infectious Diseases (1990) 9: Moellering RC: Emergence of enterococcus as a significant pathogen. Clinical Infectious Diseases (1992) 14: Leclercq R, Derlot E, Duval J, Courvalin P: Plasmidmediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New England Journal of Medicine (1988) 319: Uttley AH, Collins CH, Naidoo J, George RC: Vancomycinresistant enterococci. Lancet (1988) i: Bell JM, Paton JC, Turnidge J: Emergence of vancomycinresistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. Journal of Clinical Microbiology (1998) 36: Liassine N, Frei R, Jan I, Auckenthaler R: Characterization of glycopeptide-resistant enterococci from a Swiss hospital. Journal of Clinical Microbiology (1998) 36: Torell E, Fredlund H, Tornquist E, Myhre EB, Sjoberg L, Sundsfjord A: Intrahospital spread of vancomycin-resistant Enterococcus faecium in Sweden. Scandinavian Journal of Infectious Diseases (1997) 29 : Lavery A, Rossney AS, Morrison D, Power A, Keane CT: Incidence and detection of multi-drug resistant enterococci in Dublin hospitals. Journal of Medical Microbiology (1997) 46: Vandamme P, Vercauteren E, Lammens C, Pensart N, Ieven M, Pot B, Leclercq R, Goossens H: Survey of enterococcal susceptibility patterns in Belgium. Journal of Clinical Microbiology (1999) 34 : Allerberger F, Lass FC, Dierich MP, Hirschl AM, Presterl E, Haas G, Klare I, Witte W: Vancomycin-resistant enterococci in Austria. Wiener Klinische Wochenschrift (1997) 109: Gordts B, Van-Landuyt H, Ieven M, Vandamme P, Goossens H: Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. Journal of Clinical Microbiology (1995) 33: Klare I, Witte W: Glycopeptidresistente Enterokokken: zur Situation in Deutschland. Hygiene und Microbiologie (1997) 1: Wallrauch C, Elsner E, Milatovic D, Cremer J, Braveny I: Antibiotic resistance of enterococci in Germany. Medizin und Klinik (1997) 92: Boisivon A, Thibault M, Leclercq R: Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clinical Microbiology and Infection (1997) 3: McNamara EB, King EM, Smyth EG: A survey of antimicrobial susceptibility of clinical isolates of Enterococcus spp. from Irish hospitals. Journal of Antimicrobial Chemotherapy (1995) 35: Endtz HP, van-den-braak N, van-belkum A, Kluytmans JA, Koeleman JG, Spanjaard L, Voss A, Weersink AJ, Vandenbroucke GC, Buiting AG, van Duin A, Verbrugh HA: Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands. Journal of Clinical Microbiology (1997) 35: Fontana R, Ligozzi M, Mazzariol A, Veneri G, Cornaglia G: Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. Clinical Infectious Diseases (1998) 27, Supplement 1: Marcus N, Peled N, Yagupsky P: Rapid increase in the prevalence of antimicrobial drug resistance among enterococcal blood isolates in Southern Israel. European Journal of Clinical Microbiology & Infectious Diseases (1997) 16: Fujita N, Yoshimura M, Komori T, Tanimoto K, Ike Y: First report of the isolation of high-level vancomycin-resistant Enterococcus faecium from a patient in Japan. Antimicrobial Agents and Chemotherapy (1998) 42: Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, Eisner W, Warren S, Kreiswirth B: Emergence of vancomycin-resistant enterococci in New York City. Lancet (1993) 342: Centers for Disease Control and Prevention: Nosocomial enterococci resistant to vancomycin United States, Morbidity and Mortality Weekly Report (1993) 42: McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR: Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerging Infectious Diseases (1997) 3: Woodford N, Johnson AP, Morrison D, Speller DC, Woodford N, Johnson AP, Morrison D, Speller DC: Current perspectives on glycopeptide resistance. Clinical Microbiology Reviews (1995) 8 : Bates J, Jordens Z, Selkon JB: Evidence for an animal origin of vancomycin-resistant enterococci. Lancet (1993) 342: Donnelly JP, Voss A, Witte W, Murray BE: Does the use of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? Journal of Antimicrobial Chemotherapy (1996) 37: Chadwick PR, Woodford N, Kaczmarski EB, Gray S, Barrell RA, Oppenheim BA: Glycopeptide-resistant enterococci isolated from uncooked meat. Journal of Antimicrobial Chemotherapy (1996) 38:
7 Taylor ME, Oppenheim BA, Chadwick PR, Weston D, Palepou MF, Woodford N, Bellis M: Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. Journal of Hospital Infection (1999) 42: Facklam RR, Collins MD: Identification of Enterococcus species isolated from human infections by a conventional test scheme. Journal of Clinical Microbiology (1989) 27: Devriese LA, Pot B, Kersters K: Acidification of methyl-dglucopyranoside: a useful test to differentiate Enterococcus casseliflavus and Enterococcus gallinarum from Enterococcus faecium species group and from Enterococcus faecalis. Journal of Clinical Microbiology (1996) 34: Bongaerts GP, Hoogkamp JA: In vitro activities of Bay Y3118, ciprofloxacin, ofloxacin and flerofloxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrobial Agents and Chemotherapy (1993) 37: Dutka-Malem S, Evers S, Courvalin P: Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. Journal of Clinical Microbiology (1995) 33: Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I: Methicillin-resistant Staphylococcus aureus in Europe. European Journal of Clinical Microbiology & Infectious Diseases (1994) 13: Tokars JI, Satake S, Rimland D, Carson L, Miller ER, Killum E, Sinkowitz-Cochran RL, Arduino MJ, Tenover FC, Marston B, Jarvis WR: The prevalence of colonization with vancomycin-resistant enterococcus at a Veterans Affairs institution. Infection Control and Hospital Epidemiology (1999) 20:
Antimicrobial Susceptibility Patterns of Enterococci Causing Infections in Europe
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2542 2546 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Antimicrobial Susceptibility
More informationDepartment of Clinical Bacteriology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of Heraklion, Crete, Greece
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00992.x Emergence of vancomycin-resistant enterococci in a tertiary hospital in Crete, Greece: a cluster of cases and prevalence study on intestinal colonisation
More informationFrank Møller Aarestrup
Danish Veterinary Laboratory Bacterial populations and resistance development: Intestinal tract of meat animals Frank Møller Aarestrup 12 Antibiotic production 10 Mill. Kg 8 6 4 2 0 50 52 54 56 58 60 62
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationMRSA in the United Kingdom status quo and future developments
MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L
More informationDecrease of vancomycin resistance in Enterococcus faecium from bloodstream infections in
AAC Accepted Manuscript Posted Online 30 March 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.00513-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Decrease of vancomycin
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationProf. Otto Cars. We are overconsuming a global resource. It is a collective responsibility by governments, supranational organisatons
What are the consequences of rising antibiotic resistance for Sweden? Prof. Otto Cars Chairman The Swedish Strategic programme against antibiotic resistance (Strama) We are overconsuming a global resource
More informationAntibiotic resistance: the rise of the superbugs
Antibiotic resistance: the rise of the superbugs Allen Cheng Associate Professor of Infectious Diseases Epidemiology, Alfred Health; Monash University About me Specialist in infectious diseases Head, Infection
More informationA web-based interactive tool to explore antibiotic resistance and consumption via maps and charts
http://resistancemap.cddep.org A web-based interactive tool to explore antibiotic resistance and consumption via maps and charts CDDEP first developed ResistanceMap in 21. The new ResistanceMap now includes
More informationANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES
ENTEROCOCCAL SPECIES Sample ES-02 was a simulated blood culture isolate from a patient with symptoms of sepsis. Participants were asked to identify any potential pathogen and to perform susceptibility
More informationThe challenge of growing resistance
EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three
More informationSUPPLEMENT ARTICLE. Donald E. Low, 1 Nathan Keller, 2 Alfonso Barth, 3 and Ronald N. Jones 4
SUPPLEMENT ARTICLE Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997 1999 Donald E.
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationHealth Service Executive Parkgate St. Business Centre, Dublin 8 Tel:
Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel: 01 635 2500 www.hse.ie Health Service Executive Oak House, Millennium Park, Naas, Co. Kildare Tel: 045 880 400 www.hse.ie The prevention
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationJAC Enterococci with reduced susceptibility to vancomycin in New Zealand
Journal of Antimicrobial Chemotherapy (2000) 46, 405 410 JAC Enterococci with reduced susceptibility to vancomycin in New Zealand Kere Kobayashi a, Min Rao a, Stefanie Keis a, Frederick A. Rainey b, John
More informationH.C. Wegener, F.M. Aarestrup, L.B. Jensen, A.M. Hammerum and F. Eager. Danish Veterinary Laboratory Bulowsvej 27, DK-1790 Copenhagen V, Denmark
Journal of Animal and Feed Sciences, 7, 1998, 7-14 The association between the use of antimicrobial growth promoters and development of resistance in pathogenic bacteria towards growth promoting and therapeutic
More informationEuropean poultry industry trends
European poultry industry trends November 5 th 2014, County Monaghan Dr. Aline Veauthier & Prof. Dr. H.-W. Windhorst (WING, University of Vechta) 1 Agenda The European Chicken Meat Market - The global
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationConsumption of antibiotics in hospitals. Antimicrobial stewardship.
Consumption of antibiotics in hospitals. Antimicrobial stewardship. Inge C. Gyssens MD PhD Radboud university medical center, Nijmegen, The Netherlands Hasselt University, Belgium 1. Antibiotic use in
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union November 2012 Highlights on antibiotic consumption Antibiotic use is one of the main factors responsible for the development and
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationQuelle politique antibiotique pour l Europe? Dominique L. Monnet
Quelle politique antibiotique pour l Europe? Dominique L. Monnet National Center for Antimicrobials & Infection Control Statens Serum Institut, Copenhagen, Denmark Opinion of the Section for Protection
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationAre Clinical Laboratories in California Accurately Reporting Vancomycin-Resistant Enterococci?
JOURNAL OF CLINICAL ROBIOLOGY, Oct. 1997, p. 2526 2530 Vol. 35, No. 10 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Are Clinical Laboratories in California Accurately Reporting
More informationESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
More informationAgent-Resistant Enterococci
JOURNAL OF CLINICAL MICROBIOLOGY, July 1993, p. 1695-1699 0095-1137/93/071695-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 31, No. 7 Ability of Clinical Laboratories To Detect Antimicrobial
More informationSusceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System
Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationJan A. Jacobs* and Ellen E. Stobberingh
Journal of Antimicrobial Chemotherapy (996) 37, 37-375 In-vitro antimicrobial susceptibility of the 'Streptococcus millerv group {Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius)
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationPneumococcus: Antibiotic Resistance in the Region
Pneumococcus: Antibiotic Resistance in the Region Çiğdem Bal Kayacan Istanbul University Istanbul Faculty of Medicine Department of Microbiology & Clinical Microbiology Drug Resistance in S.pneumoniae
More informationThe evolutionary epidemiology of antibiotic resistance evolution
The evolutionary epidemiology of antibiotic resistance evolution François Blanquart, CNRS Stochastic Models for the Inference of Life Evolution CIRB Collège de France Quantitative Evolutionary Microbiology
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationHosted by the Infection Prevention Society A Webber Training Teleclass
Broadcast Live From the Annual Conference of the Infection Prevention Society www.ips.uk.net The only drugs that are: Gary French Guy s & St Thomas Hospital & King s College, London Not directed against
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationAntibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines
Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products Annex III Surveillance
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationESCMID Online Lecture Library. by author
EUCAST and susceptibility testing Europe and beyond Gunnar Kahlmeter EUCAST, ESCMID Antimicrobial susceptibility testing To guide therapy and predict clinical outcome in individual patients (clinical breakpoints)
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More informationOccurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital
Original Article Occurrence of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Srinagarind Hospital Aroonlug Lulitanond, M.Sc. 1,3 Aroonwadee Chanawong, Ph.D. 1,3
More informationSpecies prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals
Journal of Medical Microbiology (2003), 52, 163 168 DOI 10.1099/jmm.0.04949-0 Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals Edet E. Udo, 1 Noura Al-Sweih,
More informationSUPPLEMENT ARTICLE. S114 CID 2001:32 (Suppl 2) Diekema et al.
SUPPLEMENT ARTICLE Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe,
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationEuropean Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004
European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004 SECOND ANNUAL REPORT MJ Coyne 1, SJ Dancer 1, G Edwards 2, 3, D Morrison 2. 1 Health Protection Scotland, 2 Scottish MRSA
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01550.x Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 2004)
More informationrates adjusted for age, sex, infection subclass, and type of antibiotic treatment used) by British Medical Journal Publishing Group
Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis Craig J Currie BMJ 2014;349:g5493 23 September 2014 More than one in 10 initial antibiotic monotherapies
More informationJ. W. Mouton, H. P. Endtz, J. G. den Hollander, N. van den Braak and H. A. Verbrugh
Journal of Antimicrobial Chemotherapy (1997) 39, Suppl. A, 75 80 JAC In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with
More informationWHO global and regional activities on AMR and collaboration with partner organisations
WHO global and regional activities on AMR and collaboration with partner organisations Dr Danilo Lo Fo Wong Programme Manager for Control of Antimicrobial Resistance Building the AMR momentum 2011 WHO/Europe
More informationKey words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin
Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin Table 1 Detection rate of Campylobacter from stool samples taken from sporadic diarrheic patients Table 2 Detection rates of Campylobacter
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationEFSA s activities on Antimicrobial Resistance
EFSA s activities on Antimicrobial Resistance CRL-AR, Copenhagen 23 April 2009 Annual Workshop of CRL - AR 1 Efsa s Role and Activities on AMR Scientific advices Analyses of data on AR submitted by MSs
More informationTHE DEVELOPMENT OF A RISK BASED MEAT INSPECTION SYSTEM SANCO / 4403 / 2000
FEDERATION OF VETERINARIANS OF EUROPE FVE/01/034 Final THE DEVELOPMENT OF A RISK BASED MEAT INSPECTION SYSTEM SANCO / 4403 / 2000 Members FVE COMMENTS Austria Belgium Croatia Cyprus Czech Republic Denmark
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationHSE - Health Protection Surveillance Centre Surveillance of Antimicrobial Consumption in Ireland
Surveillance of Antimicrobial Consumption in Ireland Ajay Oza A European Study on the Relationship between Antimicrobial Use and Antimicrobial Resistance (1998-1999) Bronzwaer et al 2002 Emerging Infectious
More informationANTIMICROBIAL SUSCEPTIBILITY CONTEMPORARY SUSCEPTIBILITY TESTS AND TREATMENTS FOR VRE INFECTIONS
TREATMENTS FOR VRE INFECTIONS Sample ES-01 (2015) was a simulated blood culture isolate from a patient with associated clinical symptoms (pure culture). Participants were requested to identify any potential
More informationFecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin
ISPUB.COM The Internet Journal of Infectious Diseases Volume 2 Number 2 Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin E Nahum, Z Samra, J Ben-Ari, O Dagan,
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationORIGINAL ARTICLE /j x. and 2 Department of Infectious Diseases, Westmead Hospital, Westmead, New South Wales, Australia
ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.02052.x Difficulties in detection and identification of Enterococcus faecium with low-level inducible resistance to vancomycin, during a hospital outbreak S. Pendle
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationby author ESCMID Online Lecture Library EUCAST The European Committee on Antimicrobial Susceptibility Testing September 2010
EUCAST The European Committee on Antimicrobial Susceptibility Testing September 2010 Gunnar Kahlmeter Chairman of EUCAST Terms and acronyms AST Antimicrobial Susceptibility Testing MIC Minimum Inhibitory
More informationRESULTS 2216 STOBBERINGH ET AL. ANTIMICROB. AGENTS CHEMOTHER.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1999, p. 2215 2221 Vol. 43, No. 9 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Enterococci with Glycopeptide
More informationResearch Article Risk Factors Associated with Vancomycin-Resistant Enterococcus in Intensive Care Unit Settings in Saudi Arabia
Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 369674, 4 pages http://dx.doi.org/10.1155/2013/369674 Research Article Risk Factors Associated with Vancomycin-Resistant Enterococcus
More informationDalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2
More informationOrigins of Resistance and Resistance Transfer: Food-Producing Animals.
Origins of Resistance and Resistance Transfer: Food-Producing Animals. Chris Teale, AHVLA. Origins of Resistance. Mutation Brachyspira hyodysenteriae and macrolide and pleuromutilin resistance. Campylobacter
More informationIn vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains
Eur J Clin Microbiol Infect Dis (2010) 29:503 507 DOI 10.1007/s10096-010-0886-2 ARTICLE In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationRisk Factors for New Detection of Vancomycin-Resistant Enterococci in Acute-Care Hospitals That Employ Strict Infection Control Procedures
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2003, p. 2492 2498 Vol. 47, No. 8 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.8.2492 2498.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationTECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017
TECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017 www.ecdc.europa.eu ECDC TECHNICAL REPORT External quality
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationWHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis
WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis Aim: to estimate the burden of MDROs isolated among inpatients in a wide range of health-care
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationSCIENTIFIC REPORT. Analysis of the baseline survey on the prevalence of Salmonella in turkey flocks, in the EU,
The EFSA Journal / EFSA Scientific Report (28) 198, 1-224 SCIENTIFIC REPORT Analysis of the baseline survey on the prevalence of Salmonella in turkey flocks, in the EU, 26-27 Part B: factors related to
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationEvolution of antibiotic resistance. October 10, 2005
Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart
More informationReceived 9 December 2002; returned 25 March 2003; revised 2 April 2003; accepted 30 May 2003
Journal of Antimicrobial Chemotherapy (2003) 52, 382 388 DOI: 10.1093/jac/dkg352 Advance Access publication 29 July 2003 Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationAppendix F: The Test-Curriculum Matching Analysis
Appendix F: The Test-Curriculum Matching Analysis TIMSS went to great lengths to ensure that comparisons of student achievement across countries would be as fair and equitable as possible. The TIMSS 2015
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationOvernight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
More informationChart showing the average height of males and females in various world countries.
Chart showing the average height of males and females in various world countries. Country/Region Average male height Average female height Sampled Age Range Albania 174.0 cm (5 ft 8 1/2 in) 161.8 cm (5
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationAMR epidemiological situation: ECDC update
One Health Network on Antimicrobial Resistance (AMR) AMR epidemiological situation: ECDC update Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI)
More informationEU Health Priorities. Jurate Svarcaite Secretary General PGEU
EU Health Priorities Jurate Svarcaite Secretary General PGEU Members: Professional Bodies & Pharmacists Associations 2016: 33 Countries Austria Belgium Bulgaria Croatia Cyprus Czech Rep Denmark Estonia
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationDETECTION OF VANCOMYCIN RESISTANT ENTEROCOCCI (VRE) ISOLATED FROM URINARY TRACT INFECTIONS (UTI) IN TEHRAN, IRAN
DARU Volume 14, No. 3, 2006 141 DETECTION OF VANCOMYCIN RESISTANT ENTEROCOCCI (VRE) ISOLATED FROM URINARY TRACT INFECTIONS (UTI) IN TEHRAN, IRAN 1 BAHRAM FATHOLAHZADEH, 1 FARHAD B. HASHEMI, 1 MOHAMMAD
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationMicrobiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 2003
Microbiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 3 Final report Olivier Denis and Marc J. Struelens Reference Laboratory for Staphylococci Department
More informationExploring the Role of Antibiotics on VRE Colonization and Infection
Exploring the Role of Antibiotics on VRE Colonization and Infection Dr. James McKinnell, Dr. Loren Miller, Dr. Arnold Bayer K30 Fellow Harbor-UCLA/University of Alabama Background Enterococcus Spp. are
More information